The National Research Council has recommended development of polio antiviral drugs to assist in management of outbreaks and to mitigate adverse consequences of vaccination. V-073 is a small molecule poliovirus capsid inhibitor that is being developed for these purposes. Antiviral use raises the potential of treatment-emergent resistance. Understanding virological consequences of resistance is important.
Methods
Six independent laboratory-derived V-073-resistant poliovirus variants were characterized for their ability to be neutralized by conventional vaccine-induced immune sera, to elicit serum neutralizing antibodies upon CD-1 mouse immunization, and to replicate in and to cause paralysis of TgPVR21 mice.
Results
V-073-resistant variants were effectively neutralized by oral poliovirus vaccine and inactivated poliovirus vaccine human immune sera. All variants elicited virus neutralizing antibody titres in CD-1 mice that were comparable to drug-susceptible parental and Sabin vaccine strain viruses. Infection efficiency of TgPVR21 mice by variants was comparable to (1 of 6 variants) or considerably lower than (5 of 6 variants) parental viruses. Drug-resistant variants replicated to levels comparable to (1 of 6 variants) or substantially less than (5 of 6 variants) their drug-susceptible parental viruses and were on average 1.4 log10 (range 0.3 to >2.8 log10) less neurovirulent.
Conclusions
Laboratory-derived V-073-resistant variants exhibit clear attenuation of pathogenic properties while maintaining immunological features of drug-susceptible viruses.
References
1.
Committee on Development of a Polio Antiviral and its Potential Role in Global Poliomyelitis Eradication, National Research Council.Exploring the role of antiviral drugs in the eradication of polio: workshop report. Washington: The National Academies Press2006. (Accessed 14 June 2011.) Available from http://www.nap.edu/catalog/php?record_id=11599.
2.
ObersteM.S., MooreD., AndersonB.In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother2009; 53: 4501–4503.
World Health Organization.Manual for the virological investigation of polio. WHO/EPI/GEN/97.01. Geneva: World Health Organization1997. (Accessed 14 June 2011.) Available from http://whqlibdoc.who.int/hq/1997/WHO_EPI_GEN_97.01.pdf.
5.
Maintenance and distribution of transgenic mice susceptible to human viruses. Bull World Health Organ1993; 71: 497–502.
6.
Committee for the Update of the Guide for the Care and Use of Laboratory Animals, National Research Council.Guide for the care and use of laboratory animals. 8th ed.Washington: National Academies Press2010. (Accessed 14 June 2011.) Available from http://www.nap.edu/catalog.php?record_id=12910.
7.
IvanovA., DragunskyE., IvanovaO.Determination of poliovirus-specific IgA in saliva by ELISA tests. J Virol Methods2005; 126: 45–52.
8.
RezapkinG., NeverovA., CherkasovaE.Repertoire of antibodies against type 1 poliovirus in human sera. J Virol Methods2010; 169: 322–331.
9.
RenR.B., CostantiniF., GorgaczE.J., LeeJ.J., RacanielloV.R.Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell1990; 63: 353–362.
10.
KoikeS., TayaC., KurataT.Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A1991; 88: 951–955.
11.
RenR., RacanielloV.R.Poliovirus spreads from muscle to the central nervous system by neural pathways. J Infect Dis1992; 166: 747–752.
